2Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG 158) and an update on GOGO 182-ICON5 [J]. Int J Gynecol Cancer, 2003 ,13(6) :735-740.
3Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with eisplatin/paclitaxel versus carboplatin/paclitaxel[ J ]. J Clin Oncol, 2006 , 24 (4) :579-586.
4Le T, Leis A, Pallwa P, et al. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment [ J ]. Gynecol Oncol, 2004, 92( 3 ) :839-844.
5Bezjak A, Tu D, Bacon M,et al. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study [J]. J Clin Oncol, 2004 ,22 ( 22 ) :4595-4603.
6Pfisterer J,Weber B, Reuss A,et al. Randomized phase Ⅲ trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO[ J]. J Natl Cancer Inst, 2006 , 98(15) :1036-1045.
7Chan YM, Ng TY, Ngan HY,et al. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study [ J ]. Gynecol Oncol, 2003, 88( 1 ) :9-16.
8Wenzel EB, Huang HQ, Armstrong DK, et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2007 , 25(4) : 437-443.
9Aapro MS, Cameron DA. Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours [ J ], Eur J Cancer, 2006, 42(15) :2433-2453.
10American Society of Clinical Ontology. 2006 update of ASCO practice guideline recommendations for the use of white blood cell growth factors : guideline summary[J]. J Oncol Pract, 2006, 2(4) :196-201.
